Immunotherapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Wednesday, September 12th, 2018

6:15pm

Location:

Flemings Prime Steakhouse & Wine Bar

217 Stuart Street, Boston, MA 02116

Indication: IMFINZI is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) who disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

IMMUNIZE can cause serious, potentially fatal adverse reactions including immune-mediated pneumonitis, hepatitis, colitis or diarrhea, endocrinopathies, nephritis, rash or dermatitis, other immune-mediated adverse reactions, infection and infusion-related reactions.

To find out more or register for this meeting, please contact Susan Predaris at Susan.Predaris@astrazeneca.com or (603) 247-1306.